Abstract
This review discusses clinical and preclinical evidence that supports the use of cannabinoid receptor agonists for the management of multiple sclerosis. In addition, it considers preclinical findings that suggest that as well as ameliorating signs and symptoms of multiple sclerosis, cannabinoid CB1 and/or CB2 receptor activation may suppress some of the pathological changes that give rise to these signs and symptoms. Evidence that the endocannabinoid system plays a protective role in multiple sclerosis is also discussed as are potential pharmacological strategies for enhancing such protection in the clinic.
| Original language | English |
|---|---|
| Pages (from-to) | 45-59 |
| Number of pages | 15 |
| Journal | Molecular Neurobiology |
| Volume | 36 |
| Issue number | 1 |
| Early online date | 26 Jun 2007 |
| DOIs | |
| Publication status | Published - Aug 2007 |
Keywords
- Delta(9)-tetrahydrocannabinol
- dronabinol
- Marinol (R)
- Sativex (R)
- nabilone
- Cesamet (R)
- multiple sclerosis
- spasticity
- pain
- cannabinoid receptors
- endocannabinoids
- anandamide
- 2-arachidonoyl glycerol
- experimental autoimmune encephalomyelitis
- anandamide cellular uptake
- acid amide hydrolase
- experimental allergic encephalomyelitis autoantibodies
- orally-administered cannabinoids
- placebo-controlled trial
- chronic pain models
- head group analogs
- neuropathic pain
- CB2 receptor